March 8th 2024
On March 08, 2024, the FDA approved semaglutide 2.4 mg (Wegovy) to reduce cardiovascular risk in adults with obesity or overweight and heart disease based on the SELECT trial.
Report: More Than 1 Million Insulin Users May Have Rationed Supply in Past Year
October 18th 2022An analysis of 2021 NHIS data suggests 16.5% of adult insulin users in the US reported rationing insulin in the past year, with results providing additional insight into characteristics associated with increased likelihood of rationing, including diabetes type, patient age, racial/ethnic background, and insurance type.
Managing CKD in the Face of a Growing Diabetes Epidemic, with Amy Mottl, MD
October 17th 2022In an interview at the 6th annual Cardio-Endo-Renal Collaborative from Physicians' Education Resource, Amy Mottl, MD, provides perspective on recent data from the CURE-CKD registry and problems facing nephrologists as they cope with an increasing prevalence of diabetes.
Study Details "Troubling" Rates of Chronic Kidney Disease in People with Diabetes
October 14th 2022An analysis of data from more than 640,000 people with diabetes recorded between 2015-2020 is providing new insight into what study investigators are calling "troubling" trends in the incidence of CKD in the face a growing diabetes epidemic.
Diabetes Dialogue: EASD 2022 and CGM News
October 13th 2022In this special edition episode of Diabetes Dialogue, our hosts break down their top clinical takeaways from the European Association for the Study of Diabetes 2022 annual meeting, new data from the FLASH-UK trial, the global launch of Dexcom G7, and the announcement of US availability for the FreeStyle Libre 3.
Both Type 1 and Type 2 Diabetes Diagnoses Linked to Early Menopause
October 12th 2022An analysis of data from the Canadian Longitudinal Study on Aging provides a snapshot of the apparent increase in risk of early menopause associated with a diagnosis of either type 1 diabetes or type 2 diabetes in aging women.
Study Finds Children, Young Adults with Down Syndrome More Likely to Develop Diabetes
October 6th 2022An analysis of data from more than 9900 people with Down syndrome and 38,000 controls provides new insight into the apparent increase in risk of developing diabetes among children and young adults with Down syndrome.
In Gestational Diabetes, Quicker Time to Goal Associated with Improved Perinatal Outcomes
September 29th 2022An analysis of more than 25,000 women with gestational diabetes from a 10-year period provides insight into the impact time to optimal glycemic control on risk of adverse perinatal outcomes, including risk of cesarean delivery, shoulder dystocia, LGA, and neonatal ICU admission.
iLet Bionic Pancreas Improves Glycemic Control, Time in Target Range in Type 1 Diabetes
September 28th 2022In data published in the New England Journal of Medicine, the iLet Bionic Pancreas was associated with improved glycemic control and time in target glucose range compared to standard care in a cohort of people with type 1 diabetes aged 6-79 years of age.
Diabetes Dialogue: September 2022
September 28th 2022In this regularly scheduled September 2022 episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, provide their own perspective on DIY looping based on the results of a recent study published in the New England Journal of Medicine and also break down a new set of consensus recommendations for the use of automated insulin delivery (AID) systems in clinical practice published in Endocrine Reviews, which Isaacs helped compose as a member of the writing committee.
AACE Releases New 2022 Diabetes Management Guidelines
September 27th 2022Announced on September 27, the latest guideline recommendations on diabetes management from the American Academy of Clinical Endocrinology represent their first update on the topic since 2015 and contains 170 new or updated evidence-based recommendations.
Endocrine Month in Review: September 2022
September 25th 2022Our endocrinology month in review spotlights the most popular content from the past month. Our top content from September 2022 includes new guideline recommendations from the ADA/EASD, new data on semaglutide 2.4 mg and tirzepatide, a label update for finerenone, & more!
Studies Debate Link Between COVID-19 and Increased Type 1 Diabetes Diagnoses
September 24th 2022A pair of studies published within days of one another provide insight into the apparent increase in risk of type 1 diabetes diagnoses following COVID-19, but one study purports this increase may not be the result of COVID-19.